UI Hospitals and Clinics

Clinical Trial Details

Short Title
Darbepoetin Alfa in Anemic Subjects with Advanced Stage Non-small Cell Lung Cancer
Official Title

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy


Participants in this research study have been diagnosed with advanced stage non-small cell lung cancer and are currently receiving chemotherapy. The purpose of this study is to determine the safety of a drug called darbepoetin alfa. Approximately 3000 people will be enrolled in this study worldwide. Study involvement will last until the conclusion of the study.

Start Date
December 1, 2009
End Date
August 4, 2014
Gender Preference
Age Group
18 - 99 years
Principal Investigator
Taher Abu Hejleh, MD
Contact Info

Karen Parrott, 319-353-6347

Department or Field of Study
advanced stage ; cancer ; chemotherapy ; darbepoetin alfa ; hohl ; IRB#200903681 ; non-small cell lung cancer ; phase 3 ; phase III ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.